IFM Investors Pty Ltd Buys 780 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

IFM Investors Pty Ltd raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,651 shares of the biopharmaceutical company’s stock after acquiring an additional 780 shares during the quarter. IFM Investors Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,834,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ALNY. Allspring Global Investments Holdings LLC boosted its position in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Quent Capital LLC lifted its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $38,000. Robeco Institutional Asset Management B.V. grew its position in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $52,000. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. Cantor Fitzgerald restated a “neutral” rating and issued a $165.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $230.00 to $173.00 in a report on Friday, February 16th. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Finally, Chardan Capital lowered their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $215.88.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $0.40 during trading hours on Friday, reaching $143.31. The company had a trading volume of 479,139 shares, compared to its average volume of 467,891. The business has a fifty day moving average price of $150.21 and a 200-day moving average price of $165.79. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $218.88. The firm has a market cap of $18.05 billion, a PE ratio of -40.26 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.68) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.